Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.

Pancreatic ductal adenocarcinoma (PDAC) elicits a dense stromal response that blocks vascular access because of pericyte coverage of vascular fenestrations. In this way, the PDAC stroma contributes to chemotherapy resistance in addition to causing other problems. In order to improve the delivery of gemcitabine, a first-line chemotherapeutic agent, a PEGylated drug-carrying liposome was developed, using a transmembrane ammonium sulfate gradient to encapsulate the protonated drug up to 20% w/w. However, because the liposome was precluded from entering the xenograft site due to the stromal interference, we developed a first-wave nanocarrier that decreases pericyte coverage of the vasculature through interference in the pericyte recruiting TGF-β signaling pathway. This was accomplished using a polyethyleneimine (PEI)/polyethylene glycol (PEG)-coated mesoporous silica nanoparticle (MSNP) for molecular complexation to a small molecule TGF-β inhibitor, LY364947. LY364947 contains a nitrogen atom that attaches, through H-bonding, to PEI amines with a high rate of efficiency. The copolymer coating also facilitates systemic biodistribution and retention at the tumor site. Because of the high loading capacity and pH-dependent LY364947 release from the MSNPs, we achieved rapid entry of IV-injected liposomes and MSNPs at the PDAC tumor site. This two-wave approach provided effective shrinkage of the tumor xenografts beyond 25 days, compared to the treatment with free drug or gemcitabine-loaded liposomes only. Not only does this approach overcome stromal resistance to drug delivery in PDAC, but it also introduces the concept of using a stepwise engineered approach to address a range of biological impediments that interfere in nanocancer therapy in a spectrum of cancers.

[1]  S. Leppla,et al.  Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin , 2005, Nature Biotechnology.

[2]  M. Saint-Geniez,et al.  TGF-β Is Required for Vascular Barrier Function, Endothelial Survival and Homeostasis of the Adult Microvasculature , 2009, PloS one.

[3]  Kazunori Kataoka,et al.  Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling , 2007, Proceedings of the National Academy of Sciences.

[4]  C. Betsholtz,et al.  Endothelial/Pericyte Interactions , 2005, Circulation research.

[5]  H. Shepard,et al.  Therapeutic Targeting of Hyaluronan in the Tumor Stroma , 2012, Cancers.

[6]  Steven Song,et al.  The role of pericytes in blood-vessel formation and maintenance. , 2005, Neuro-oncology.

[7]  G. Sapkota,et al.  The specificities of small molecule inhibitors of the TGFß and BMP pathways. , 2011, Cellular signalling.

[8]  D. Darland,et al.  TGFβ is required for the formation of capillary-like structures in three-dimensional cocultures of 10T1/2 and endothelial cells , 2004, Angiogenesis.

[9]  M. V. van Zandvoort,et al.  Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots. , 2008, Cancer research.

[10]  P. Dijke,et al.  Extracellular control of TGFβ signalling in vascular development and disease , 2007, Nature Reviews Molecular Cell Biology.

[11]  R. Jain,et al.  TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma , 2012, Proceedings of the National Academy of Sciences.

[12]  Alexander A. Fingerle,et al.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications , 2012, Nature Reviews Gastroenterology &Hepatology.

[13]  Alessandro Daducci,et al.  DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content. , 2011, European journal of radiology.

[14]  Yan Song,et al.  Potent angiogenesis inhibition by the particulate form of fullerene derivatives. , 2010, ACS nano.

[15]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.

[16]  Janet Rossant,et al.  The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. , 2010, Developmental cell.

[17]  Derek S. Chan,et al.  Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer , 2012, Gut.

[18]  V. Koteliansky,et al.  Interference with TGF‐β1 and ‐β3 in tumor stroma lowers tumor interstitial fluid pressure independently of growth in experimental carcinoma , 2002, International journal of cancer.

[19]  A. Lowy,et al.  Surgery for pancreatic cancer: recent controversies and current practice. , 2005, Gastroenterology.

[20]  P. Antich,et al.  Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Y. Ouchi,et al.  Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor‐β receptor inhibitor on extravasation of nanoparticles from neovasculature , 2009, Cancer science.

[22]  D. Friend,et al.  Endocytosis of liposomes and intracellular fate of encapsulated molecules: Encounter with a low pH compartment after internalization in coated vesicles , 1983, Cell.

[23]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[24]  B. Ring,et al.  Pharmacogenomics of Gemcitabine Metabolism: Functional Analysis of Genetic Variants in Cytidine Deaminase and Deoxycytidine Kinase , 2013, Drug Metabolism and Disposition.

[25]  M. Erkan.  Understanding the stroma of pancreatic cancer: co‐evolution of the microenvironment with epithelial carcinogenesis , 2013, The Journal of pathology.

[26]  D. Mukhopadhyay,et al.  Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. , 2008, Cancer research.

[27]  M. Kano,et al.  Pericyte-coverage of human tumor vasculature and nanoparticle permeability. , 2012, Biological & pharmaceutical bulletin.

[28]  Erkki Ruoslahti,et al.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.

[29]  Hubing Shi,et al.  Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis. , 2009, Cancer research.

[30]  Richard D. Vaughan-Jones,et al.  Regulation of tumor pH and the role of carbonic anhydrase 9 , 2007, Cancer and Metastasis Reviews.

[31]  Jonathan M. Yingling,et al.  Development of TGF-β signalling inhibitors for cancer therapy , 2004, Nature Reviews Drug Discovery.

[32]  S. Filetti,et al.  Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Tianjiao Ji,et al.  Using Functional Nanomaterials to Target and Regulate the Tumor Microenvironment: Diagnostic and Therapeutic Applications , 2013, Advanced materials.

[34]  E. Sausville,et al.  SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity , 2004, Cancer Research.

[35]  Ruth Nussinov,et al.  Nanoparticle-induced vascular blockade in human prostate cancer. , 2010, Blood.

[36]  Francesco Castelli,et al.  A mechanistic study of the permeation kinetics through biomembrane models: gemcitabine-phospholipid bilayer interaction. , 2005, Journal of colloid and interface science.

[37]  Lauren A Austin,et al.  Small molecule-gold nanorod conjugates selectively target and induce macrophage cytotoxicity towards breast cancer cells. , 2012, Small.

[38]  D. Britti,et al.  Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives , 2012, International journal of nanomedicine.

[39]  R. Derynck,et al.  SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS , 2005 .

[40]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[41]  T. Kubota,et al.  Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice , 1997, Journal of surgical oncology.

[42]  W. Harris,et al.  Omega-3 Fatty Acids Prevent Pressure Overload–Induced Cardiac Fibrosis Through Activation of Cyclic GMP/Protein Kinase G Signaling in Cardiac Fibroblasts , 2011, Circulation.

[43]  Ximing J. Yang,et al.  Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. , 2005, Cancer research.

[44]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Toi,et al.  Tumor Angiogenesis: Pericytes and Maturation Are Not to Be Ignored , 2011, Journal of oncology.

[46]  Lei Xu,et al.  Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.

[47]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[48]  D. Tuveson,et al.  nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. , 2012, Cancer discovery.

[49]  H. Friess,et al.  Surgery for Recurrent Pancreatic Ductal Adenocarcinoma , 2007, Annals of surgery.

[50]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[51]  Tian Xia,et al.  Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. , 2013, ACS nano.

[52]  Tian Xia,et al.  Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. , 2011, ACS nano.

[53]  Klaas Nicolay,et al.  MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  Shiladitya Sengupta,et al.  Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells , 2012, BMC Cancer.

[55]  B. Zlokovic,et al.  Central nervous system pericytes in health and disease , 2011, Nature Neuroscience.

[56]  Sandra R. Smith,et al.  An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[57]  T. Chatila,et al.  T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy , 2012, Journal of Translational Medicine.

[58]  M. Kris,et al.  Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. , 2009, Clinical nephrology.

[59]  Robert J Gillies,et al.  Acidity generated by the tumor microenvironment drives local invasion. , 2013, Cancer research.

[60]  R. Tomasini,et al.  Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma , 2013, Proceedings of the National Academy of Sciences.

[61]  Massimo Fresta,et al.  Cytotoxic effects of Gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells , 2004, BMC Cancer.

[62]  Bonnie F. Sloane,et al.  Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. , 2012, Cancer research.

[63]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[64]  E. Jähde,et al.  pH in human tumor xenografts and transplanted rat tumors: effect of insulin, inorganic phosphate, and m-iodobenzylguanidine. , 1992, Cancer research.